Replies to post #25632 on Biotech Values

[DewDiligence]

For an ADPC indication they would presumably have to run at least one more large clinical trial in that setting. As such a trial has not yet been designed, two years to approval is out of the question. You are probably talking about four years, minimum. And that’s assuming it is worth pursuing at all, which depends on the P-11 data. Regards, Dew